Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,049 across all filing types
Latest filing 2019-12-16 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about a certificate of compliance issued by a European regulator (SUKL) for Glenmark's manufacturing facility. It is a compliance update related to regulatory inspection and certification, not a financial report, earnings release, or management discussion. The document is short (1763 characters) and serves as an official notification rather than a detailed report. It does not contain financial data or detailed management information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents.
2019-12-16 English
Related Party Transactions
Audit Report / Information Classification · 90% confidence The document contains detailed disclosures about related party transactions, including key management personnel and enterprises influenced by them, as required by Ind AS-24 'Related Party Disclosures'. This type of information is typically part of the notes to financial statements or audit-related disclosures rather than a full annual or interim report. The document length is short (2210 characters) and focuses solely on related party transactions without broader financial data or management discussion. It does not appear to be an announcement or a certification but a standalone disclosure related to audit or accounting principles. Therefore, it fits best under Audit Report / Information (AR). H1 2020
2019-12-11 English
Registrar & Share Transfer Agent Update
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges notifying them of a change in the name of the company's Registrar and Share Transfer Agent. It does not contain financial data, management discussion, voting results, or any report content. It is an official announcement related to corporate services and compliance. Given the nature and length of the document, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-12-10 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated November 26, 2019, announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for Metformin Hydrochloride Extended-Release Tablets. It is addressed to stock exchanges and includes a media release. The content is a corporate announcement about regulatory approval of a pharmaceutical product, not a financial report, earnings release, or management discussion. The document is relatively short (3975 characters) and serves as a public announcement of a significant corporate event. It does not contain financial statements, management analysis, or detailed investor information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-11-26 English
ESOP/ESOS/ESPS
Remuneration Information Classification · 95% confidence The document text is very short (672 characters) and contains details about an Employee Stock Options Scheme, including number of options granted, vesting period, exercise period, and exercise price. This information pertains to share-based compensation plans rather than financial results, management changes, or regulatory filings. It does not represent a full report or announcement of a report publication. The content aligns best with a Remuneration Information filing, which covers compensation details for executives and directors, including stock option schemes.
2019-11-14 English
Financial Result Updates
Regulatory Filings
2019-11-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.